Hans Eriksson, MD, PhD | Psychiatrist.com

Original Research

Brexpiprazole in MDD—Metabolic Parameters and Weight

October 1, 2019

Adjunctive atypical antipsychotics can increase antidepressant response in depressed patients, but may cause adverse metabolic effects. This study examines the metabolic effects of adjunctive brexpiprazole in patients with major...

John W. Newcomer, Hans Eriksson, Peter Zhang, et al

Original Research

Reliability and Validity of the Sheehan Irritability Scale in MDD

August 24, 2016

Irritability may influence the course of MDD. Find out whether the Sheehan Irritability Scale can help researchers better determine treatment response in patients with MDD.

Sajjad A. Khan, Dennis A. Revicki, Mariam Hassan, et al

Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

Michael E. Thase, James M. Youakim, Aleksandar Skuban, et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

Michael E. Thase, James M. Youakim, Aleksandar Skuban, et al

Original Research

Extended Release Quetiapine Fumarate in Patients With Major Depressive Disorder: Suicidality Data From Acute and Maintenance Studies

May 15, 2014

Richard Weisler, Stuart A. Montgomery, Willie R. Earley, et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of High-Dose Quetiapine in Patients With Persistent Symptoms of Schizophrenia or Schizoaffective Disorder

June 14, 2011

William G. Honer, G. William MacEwan, Alain Gendron, et al